分享产品介绍 评论(0)
宿主来源
Human分子别名
Ofatumumab浓度
2mg/mL表达宿主
HEK293活性
Immobilized CD20 Flag&His Tag Protein, Human (Detergent) at 5.0μg/mL (100μL/well) can bind Anti-Human CD20 Monoclonal Antibody (Ofatumumab) (Cat. No. UA016165) with EC50 of 0.76-1.64 ng/mL.标记
Unconjugated性状
Liquid缓冲体系
PBS pH7.4, containing no preservative
储存条件
2 to 8 °C for 2 weeks under sterile conditions;
-20 °C for 3 months under sterile conditions;
-80 °C for 24 months under sterile conditions.
Please avoid repeated freeze-thaw cycles.
文献引用
1. Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557.
2. Gärtner J, Hauser SL, Bar-Or A, Montalban X, Cohen JA, Cross AH, Deiva K, Ganjgahi H, Häring DA, Li B, Pingili R, Ramanathan K, Su W, Willi R, Kieseier B, Kappos L. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. Mult Scler. 2022 Sep;28(10):1562-1575.
Ofatumumab is a fully humanized monoclonal antibody that targets the CD20 molecule on the surface of B cells. Its core mechanism of action involves binding to the CD20 protein, thereby triggering multiple effector functions—including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis—to efficiently deplete CD20-positive B lymphocytes. Clinically, ofatumumab has a dual application: the intravenous formulation (Arzerra®) is indicated for the treatment of chronic lymphocytic leukemia, while the subcutaneous formulation (Kesimpta®) has been approved for the management of adult relapsing forms of multiple sclerosis, effectively reducing relapse rates and delaying disability progression. Notably, its convenient once‑monthly, at‑home self‑administration regimen offers significant advantages in facilitating long‑term disease management for patients with multiple sclerosis.
ELISA
Immobilized CD20 Flag&His Tag Protein, Human (Detergent) at 5.0μg/mL (100μL/well) can bind Anti-Human CD20 Monoclonal Antibody (Ofatumumab) (Cat. No. UA016165) with EC50 of 0.76-1.64 ng/mL.
评论(0)